Buoyant Bayer ups key drug sales forecast
This article was originally published in Scrip
Executive Summary
Bayer reported a fall in fourth-quarter earnings for 2013, but the company is ended its 150th anniversary year in celebratory mode by announcing ambitions for its key products and R&D in 2014. Notably, it has upped its guidance for peak sales of its four growth-driving recently launched medicines by more than a third to €7.5bn or more.